News · Longevity & Aging
Engineered immune cells improved rheumatoid arthritis in all six patients in a first safety trial
CAR T therapy rebuilds the immune system in cancer. A six-person trial tested it in severe rheumatoid arthritis that no drug had controlled, and everyone improved after stopping their other treatments.
- A phase 1 safety trial in six adults whose rheumatoid arthritis had resisted standard drugs.
- Each received one infusion of their own T cells, engineered to wipe out the B cells that make harmful antibodies.
- All six had mild or moderate cytokine release syndrome; nobody had nerve side effects or a serious adverse event.
- Disease activity improved in all six after they stopped their arthritis drugs, with remission in three.
- Six patients, under a year of follow-up: a safety signal, not proof that the therapy works.
Rheumatoid arthritis is usually controllable. For a minority it is not: joints stay swollen and painful through one drug after another, and each new treatment buys less than the last. Those are the patients in this trial.
A phase 1 study in Nature Medicine took six of them off their arthritis drugs entirely and gave each a single infusion of their own immune cells, re-engineered to destroy the cells that drive the disease. The main goal was to see whether it was safe. It was, and everyone improved.
What rheumatoid arthritis is and why some cases resist treatment
MedlinePlus describes rheumatoid arthritis (RA) as a form of arthritis that causes pain, swelling, and stiffness in your joints. It affects the lining of your joints and damages the tissue that covers the ends of the bones in a joint, and the inflammation can reach the eyes, skin, heart, nerves, blood or lungs.
Part of that attack comes from antibodies the body makes against its own proteins. The patients here had anti-citrullinated protein antibodies, one such marker, and disease that had not responded to standard drugs. The authors note that CAR T cell-mediated B cell depletion has demonstrated efficacy in several autoimmune diseases, which is the idea being tested.
How the CAR T arthritis trial worked
Six patients (three men, three women) with severe, treatment-refractory disease took part. Each had T cells collected, engineered to carry a receptor that recognizes CD19, a marker on B cells, then grown and infused back after a short course of chemotherapy to clear space for them.
Crucially, they stopped all disease-modifying antirheumatic drug treatments beforehand, so any improvement could not be credited to those. The primary endpoints were the incidence and severity of cytokine release syndrome (CRS), nerve-related side effects and other adverse events in the first four weeks. Patients were followed for 36 to 52 weeks.
What happened to safety and symptoms
The side effects were the expected ones, at the milder end. CRS occurred in all patients and was limited to grade 1 and 2 events, and no nerve side effects or serious adverse events occurred. One patient had a dose-limiting toxicity, a temporary rise in liver enzymes that resolved.
The disease response was the striking part. B cells disappeared from blood and tissue, autoantibody levels fell, and despite cessation of immunosuppressive treatments, disease activity improved in all patients. Three of the six reached remission on a standard disease activity score and met the American College of Rheumatology’s 70% improvement mark.
Why a six-person arthritis trial is being taken seriously
CAR T therapy was built for blood cancers, where it can clear disease that nothing else touches. Turning it on autoimmune disease means using it not to kill a tumor but to reset an immune system that has learned the wrong lesson.
What makes this early result notable is that patients improved after stopping the drugs they had been depending on. The authors conclude that CD19 CAR T cells showed acceptable short-term tolerability in patients with treatment-refractory RA, justifying further evaluation, and the trial has moved to its next phase.
What a six-person CAR T trial cannot show
Six people is six people. There was no comparison group, no blinding, and patients who volunteer for an intensive cell therapy tend to be motivated and closely monitored, all of which can flatter results.
Follow-up ran under a year, so nobody knows whether remission lasts or how often the disease returns as B cells regrow. Rare but serious risks of CAR T therapy, including severe infections and, over years, secondary cancers, cannot be assessed in a group this size. The treatment also involves chemotherapy, hospital admission and specialist manufacturing, which limits who could ever receive it.
What this changes for people with rheumatoid arthritis
Nothing today. For the large majority, current drugs work, and the sensible path stays early treatment, regular monitoring and adjustment when a drug fails.
For the minority whose disease resists everything, this is the clearest sign yet that a one-time immune reset is worth testing properly. The next question is whether a randomized trial shows the same thing, and at what cost in risk.
People also ask
What did the study find?
Cytokine release syndrome occurred in all patients but was limited to grade 1 and 2 events. No immune effector cell-associated neurotoxicity syndrome and no serious adverse events occurred; one dose-limiting toxicity, a grade 3 rise in liver enzymes, resolved. Disease activity improved in all six patients, with a median 34% reduction in DAS28-CRP and remission plus an American College of Rheumatology 70% response in three of six.
What is CAR T cell therapy?
A patient's own T cells are collected, engineered to recognize a target on other cells, then infused back. Here the target was CD19, a marker on B cells, the cells that produce antibodies.
Why target B cells in arthritis?
In this form of rheumatoid arthritis, B cells make antibodies against the body's own proteins. Wiping the B cell population out and letting it regrow is meant to reset that response.
What is cytokine release syndrome?
A flare of immune signaling molecules after the engineered cells activate, causing fever and sometimes low blood pressure. Grades 1 and 2 are the milder end and are usually managed in hospital.
Did patients stay off their arthritis drugs?
They stopped disease-modifying drugs before treatment, and improvement was recorded despite that. Follow-up ran 36 to 52 weeks, so durability beyond a year is unknown.
Is this available?
No. This is an early-stage trial in six people, and the therapy requires specialist cell-manufacturing centers. Trials continue. This is general information rather than medical advice.